GPC-3 in hepatocellular carcinoma: current perspectives

Glypican-3 (GPC3), a member of heparan sulfate proteoglycans, attaches to the cell membrane and is frequently observed to be elevated in hepatocellular carcinoma (HCC). However, GPC3 is not detected in normal liver tissues and benign liver lesions. Consequently, GPC3 is currently being used as a diagnostic biomarker and HCC-specific positron emission computed tomography probe to identify HCCs in normal liver tissues and benign liver lesions. The overexpression of GPC-3 in serum or liver tissue also predicts poor prognosis for HCC patients. In addition, GPC3 promotes HCC growth and metastasis by activating the canonical Wnt and other signaling pathways. Targeting of GPC3, including GC33, HN3 and YP7, might offer new immunotherapeutic tools for HCC treatment.

[1]  Ching-Lung Lai,et al.  Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region , 2016, Gut and liver.

[2]  Mitchell Ho,et al.  Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis , 2015, Nature Communications.

[3]  Li-xin Wei,et al.  Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. , 2014, World journal of gastroenterology.

[4]  B. Shi,et al.  Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[5]  K. Chijiiwa,et al.  Prognostic significance of circumferential cell surface immunoreactivity of glypican‐3 in hepatocellular carcinoma , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[6]  M. Nieto,et al.  Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. , 2009, The Journal of clinical investigation.

[7]  Xiao-li Zhang,et al.  Oncogenic activation of glypican‐3 by c‐Myc in human hepatocellular carcinoma , 2012, Hepatology.

[8]  Ping Xu,et al.  Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. , 2008, Developmental cell.

[9]  P. Zhao,et al.  Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. , 2011, International journal of molecular medicine.

[10]  S. Dooley,et al.  Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. , 2015, International journal of oncology.

[11]  H. Aburatani,et al.  Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. , 2009, Biochemical and biophysical research communications.

[12]  Mitchell Ho,et al.  Glypican‐3 antibodies: A new therapeutic target for liver cancer , 2014, FEBS letters.

[13]  J. Filmus,et al.  Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo , 2008, International journal of cancer.

[14]  T. Mohr,et al.  Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis , 2011, Hepatology.

[15]  B. Peng,et al.  Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. , 2013, Surgery.

[16]  J-W Liu,et al.  Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis. , 2015, European review for medical and pharmacological sciences.

[17]  C. Lobe,et al.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. , 2005, Cancer research.

[18]  J. Kim,et al.  Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. , 2011, Hepato-gastroenterology.

[19]  Hiroyuki Aburatani,et al.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma , 2005, Modern Pathology.

[20]  Sijuan Zou,et al.  Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. , 2016, Bioconjugate chemistry.

[21]  M. Kojima,et al.  Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma , 2009, Cancer science.

[22]  Jing He,et al.  Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. , 2011, Neoplasia.

[23]  H. Ding,et al.  Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. , 2013, African health sciences.

[24]  Ning Li,et al.  Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. , 2012, Acta histochemica.

[25]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[26]  P. Philip,et al.  First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[27]  Mitchell Ho,et al.  Glypican-3: a new target for cancer immunotherapy. , 2011, European journal of cancer.

[28]  Hui Liu,et al.  Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. , 2010, World journal of gastroenterology.

[29]  H. Aburatani,et al.  Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. , 2008, Cancer research.

[30]  B. Peng,et al.  Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis , 2014, BMC Cancer.

[31]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[32]  Wei Cheng,et al.  Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. , 1997, Cancer research.

[33]  M. Tsuchiya,et al.  Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization , 2010, Anti-cancer drugs.

[34]  L. Terracciano,et al.  Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. , 2008, American journal of clinical pathology.

[35]  J. Filmus,et al.  Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. , 2008, The Biochemical journal.

[36]  S. Minoshima,et al.  Glypican-3–Targeted 89Zr PET Imaging of Hepatocellular Carcinoma , 2014, The Journal of Nuclear Medicine.

[37]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[38]  J. Filmus,et al.  Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma , 2013, The FEBS journal.